Current constitutional documents
Most recent admission document
Details of Any Other Exchanges or Trading Platforms
The company is not quoted on any other exchanges or trading platforms
Details of any Restrictions on the Transfer of Securities
There are no restrictions on the transfer of Abingdon Health securities
Whether the Company is subject to the UK City Code on Takeovers and Mergers
The company is subject to the UK City Code on Takeovers and Mergers
Country of Incorporation and Main Country of Operation
Abingdon Health was incorporated in England and Wales on 16 January 2008 (Registration No. 06475379) and is headquartered in York, UK, with an additional site in Doncaster.
Number of Securities in Issue
Issued share capital consists of 251,077,850 ordinary shares of 0.025p each as at 31 December 2025.
AIM securities not in public hands
In so far as the Company is aware, the percentage of AIM securities not in public hands is 44.1% as at 31 December 2025.
Significant Shareholders (3% or over)
As at 31 December 2025, the Company is aware of the following significant shareholders of the issued share capital of the Company:
| Shareholder | Ordinary Shares | Issued Share Capital (%) |
|---|---|---|
| Octopus Investments Limited | 44,606,013 | 17.77% |
| Cannacord Genuity Wealth Mgt | 43,702,013 | 17.41% |
| Enterprise Ventures (General Partner NPIF YHTV Equity) Ltd / Mercia | 18,071,164 | 7.20% |
| Rathbones Investment Mgt | 17,699,287 | 7.05% |
| Chris Hand | 13,678,467 | 5.45% |
This information was last updated on 6th January 2026.
Description of business
Board and Governance
Documents and Reports
Regulatory Announcements
Advisors
Nominated Advisor and Broker:
Cavendish Capital Markets Limited
One Bartholomew Close
London
EC1A 7BL
Solicitors to the Company:
Squire Patton Boggs (UK) LLP
6 Wellington Place
Leeds
LS1 4AP
Reporting Accountant and Auditor:
RSM UK Audit LLP
Fifth Floor
Central Square
29 Wellington Street
Leeds
LS1 4DL
Registrar:
MUFG Corporate Markets
Central Square
29 Wellington St
Leeds
LS1 4DL
Financial Press Office:
For all investor relations enquiries, please contact [email protected].
